Should Value Investors Buy DaVita (DVA) Stock?

02.01.25 15:40 Uhr

Werte in diesem Artikel
Aktien

147,45 EUR 2,00 EUR 1,38%

Indizes

5.942,5 PKT 73,9 PKT 1,26%

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.One stock to keep an eye on is DaVita (DVA). DVA is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock is trading with a P/E ratio of 13.33, which compares to its industry's average of 21.89. Over the last 12 months, DVA's Forward P/E has been as high as 15.26 and as low as 12.18, with a median of 14.02.Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. DVA has a P/S ratio of 0.97. This compares to its industry's average P/S of 1.37.Finally, investors will want to recognize that DVA has a P/CF ratio of 8.17. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 24.11. DVA's P/CF has been as high as 9.16 and as low as 6.71, with a median of 8.16, all within the past year.These are just a handful of the figures considered in DaVita's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that DVA is an impressive value stock right now.Just Released: Zacks Top 10 Stocks for 2024Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf DaVita HealthCare Partners

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DaVita HealthCare Partners

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu DaVita HealthCare Partners Inc

Wer­bung

Analysen zu DaVita HealthCare Partners Inc

DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
27.04.2015DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
18.10.2011DaVita outperformRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
04.11.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
06.08.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.03.2015DaVita HealthCare Partners HoldDeutsche Bank AG
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DaVita HealthCare Partners Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"